Novo Nordisk

Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes

Awiqli® offers children 10 years and older a once-weekly basal insulin alternative, reducing basal injection frequency from seven times per week to…